AstraZeneca breast cancer drug meets primary and secondary endpoints in new trial

Drugmaker AstraZeneca said on Monday that positive high-level results from a new trial of its Enhertu breast cancer drug had demonstrating a "statistically significant and clinically meaningful improvement" in progression-free survival.

AstraZeneca stated the DESTINY-Breast02 Phase III trial on Enhertu, jointly developed and commercialised with Daiichi Sankyo, also met the key secondary endpoint of improved overall survival.

The FTSE 100-listed firm said the trial evaluated a similar later-line patient population as its previous single-arm DESTINY-Breast01 Phase II trial, which was the basis for initial approvals in advanced HER2-positive metastatic breast cancer.

AZN added that the safety profile of Enhertu in DESTINY-Breast02 was consistent with previous Phase III clinical trials, with no new safety concerns identified.

Executive Vice President of oncology Susan Galbraith said: "The DESTINY-Breast02 trial results in this patient population with advanced disease confirm the efficacy and safety profile seen in DESTINY-Breast01 and are consistent with the results seen across our broader clinical programme in HER2-positive metastatic breast cancer. These data further strengthen our confidence in Enhertu and reinforce its potential to transform patient outcomes across multiple treatment settings."

Reporting by Iain Gilbert at Sharecast.com